The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13612 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Adi Alfandari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Translational Oncology Laboratory, Hematology Institute, Meir Medical Center, Kfar Saba, Israel. Hauptthemen laut MEDLINE: Genes, Tumor Suppressor, Iodide Peroxidase, Ovarian Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dotan Research grant, Cancer Biology Research Center (CBRC), Tel-Aviv University, Israel, Cancer Biology Research Center, Tel Aviv University.
Abstract (Originalsprache)
The selenoenzyme type I iodothyronine deiodinase (DIO1) catalyzes removal of iodine atoms from thyroid hormones. Although DIO1 action is reported to be disturbed in several malignancies, no work has been conducted in high‐grade serous ovarian carcinoma (HGSOC), the most lethal gynecologic cancer. We studied DIO1 expression in HGSOC patients [The Cancer Genome Atlas (TCGA) data and tumor tissues], human cell lines (ES‐2 and Kuramochi), normal Chinese hamster ovarian cells (CHO‐K1), and normal human fallopian tube cells (FT282 and FT109). To study its functional role, DIO1 was overexpressed, inhibited [by propylthiouracil (PTU)], or knocked down (KD), and cell count, proliferation, apoptosis, cell viability, and proteomics analysis were performed. Lower DIO1 levels were observed in HGSOC compared to normal cells and tissues. TCGA analyses confirmed that low DIO1 mRNA expression correlated with worse survival and therapy resistance in patients. Silencing or inhibiting the enzyme led to enhanced ovarian cancer proliferation, while an opposite effect was shown following DIO1 ectopic expression. Proteomics analysis in DIO1 ‐KD cells revealed global changes in proteins that facilitate tumor metabolism and progression. In conclusion, DIO1 expression and ovarian cancer progression are inversely correlated, highlighting a tumor suppressive role for this enzyme and its potential use as a biomarker in this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Oncology Laboratory, Hematology Institute, Meir Medical Center, Kfar Saba, Israel.
- Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine, Tel Aviv University, Israel.
- School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Israel.
- Department of Pathology, Meir Medical Center, Kfar Saba, Israel.
- Division of Gynecologic Oncology, Meir Medical Center, Kfar Saba, Israel.
- Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel.
ORCID-Profile: Osnat Ashur-Fabian
Förderung
- Dotan Research grant, Cancer Biology Research Center (CBRC), Tel-Aviv University, Israel
- Cancer Biology Research Center, Tel Aviv University
Zitieren
APA
Alfandari, A., Moskovich, D., Weisz, A., Katzav, A., Kidron, D., Beiner, M., Josephy, D., Asali, A., Hants, Y., Yagur, Y., Weitzner, O., Ellis, M., Itchaki, G., & Ashur-Fabian, O. (2024). The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13612
Vancouver
Alfandari A, Moskovich D, Weisz A, Katzav A, Kidron D, Beiner M, et al. The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer. Molecular Oncology. 2024. doi:10.1002/1878-0261.13612
BibTeX
@article{Alfandari2024,
author = {Alfandari, Adi and Moskovich, Dotan and Weisz, Avivit and Katzav, Aviva and Kidron, Debora and Beiner, Mario and Josephy, Dana and Asali, Aula and Hants, Yael and Yagur, Yael and Weitzner, Omer and Ellis, Martin and Itchaki, Gilad and Ashur-Fabian, Osnat},
title = {The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13612}
}
EUVIMED